Destiny Matthew
Papers
1
Total Citations
2
H-Index
1
About
Destiny Matthew is a pioneering translational researcher at the intersection of interventional oncology and precision medicine, with a primary focus on prostate cancer therapeutics. Her most notable contribution is the development and first-in-human validation of a novel intraprostatic, MR-guided implantable microdevice (IMD) for multidrug testing. In her landmark 2024 proof-of-concept study, Matthew demonstrated the safety and feasibility of percutaneously placing this microdevice to evaluate *in situ* intratumor responses to multiple systemic therapy agents simultaneously in men with intermediate- and high-risk localized prostate cancer. This work represents a paradigm shift from systemic trial-and-error to localized, real-time drug sensitivity testing, potentially enabling personalized treatment selection before committing patients to full-course therapies. Though early in its citation trajectory, this study has already garnered attention for its technical ingenuity and clinical promise. Matthew’s research bridges advanced imaging, device engineering, and oncology, positioning her as a rising leader in precision interventional oncology. Her work holds profound implications for reducing overtreatment and accelerating the identification of effective drug combinations tailored to individual tumor microenvironments.
Research Focus
Key Achievements
Top Papers
- 1